Document:

exhibit_1010x20220930

 ___________ (x) x 89303519CNE000005 copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By  separate letter or electronic communication which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGEMENT TO BE  RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR  OFFER.  If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided  each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. See Schedule L8VHV5CNBV97 American Centrifuge Operating, LLC 00701 Idaho Falls ID 83415 1955 Fremont Avenue Idaho Operations Office U.S. Department of Energy Oak Ridge TN 37831 893035 200 Administration Road U.S. Department of Energy EMCBC EM-Oak Ridge 22NE000396See Block 16CP00025  11 13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS.  IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. 12. ACCOUNTING AND APPROPRIATION DATA (If required) is not extended.is extended,  Items 8 and 15, and returning Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS FACILITY CODE CODE  10B. DATED (SEE ITEM 13) 10A. MODIFICATION OF CONTRACT/ORDER NO. 9B. DATED (SEE ITEM 11) 9A. AMENDMENT OF SOLICITATION NO. CODE  8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) 7. ADMINISTERED BY (If other than Item 6)CODE 6. ISSUED BY PAGE   OF  PAGES 4. REQUISITION/PURCHASE REQ. NO.3. EFFECTIVE DATE2. AMENDMENT/MODIFICATION  NO. 5. PROJECT NO. (If applicable) 1.  CONTRACT ID CODE AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 05/31/2019 Attn: Charles Kerner 6901 Rockledge Dr Ste 800 Bethesda MD 208171867 Net Increase: $2,307,400.00 CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority)  appropriation data, etc.)  SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). E. IMPORTANT: Contractor is not is required to sign this document and return    __________________ copies to the issuing office.  ORDER NO. IN ITEM 10A. 52.232-22  --  Limitation  of  Funds x 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) X UEI:  L8VHV5CNBV97 The purpose of this incremental funding modifation is to obligate funds of +$2,307,400.00 from $153,992,788.63 by +$2,307,400.00 to $156,300,188.63.   The total contract value is hereby increased from $153,992,788.63 by $2,307,400.00 to $156,300,188.63. The restriction placed on contract performance in MOD P00019 limiting performance to 31 Aug 2022 is hereby removed.  The All other terms and conditions remain unchanged and are in full force and effect. Period of Performance: 05/31/2019 to 11/30/2022 16A. NAME  AND TITLE OF CONTRACTING OFFICER (Type or print)15A. NAME AND TITLE OF SIGNER (Type or print) 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 15B. CONTRACTOR/OFFEROR 16C. DATE SIGNED (Signature of person authorized to sign) (Signature of Contracting Officer) Jeffrey C. Fogg STANDARD FORM 30 (REV. 11/2016) Prescribed by GSA FAR (48 CFR) 53.243 Previous edition unusable Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect . 09/07/2022exhibit_1011x20220930

 ___________ (x) x 89303519CNE000005 copies of the amendment; (b) By acknowledging receipt of this amendment on each copy of the offer submitted ; or (c) By  separate letter or electronic communication which includes a reference to the solicitation and amendment numbers.  FAILURE OF YOUR ACKNOWLEDGEMENT TO BE  RECEIVED AT THE PLACE DESIGNATED FOR THE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DATE SPECIFIED MAY RESULT IN REJECTION OF YOUR  OFFER.  If by virtue of this amendment you desire to change an offer already submitted , such change may be made by letter or electronic communication, provided  each letter or electronic communication makes reference to the solicitation and this amendment, and is received prior to the opening hour and date specified. See Schedule L8VHV5CNBV97 American Centrifuge Operating, LLC 00701 Idaho Falls ID 83415 1955 Fremont Avenue Idaho Operations Office U.S. Department of Energy Oak Ridge TN 37831 893035 200 Administration Road U.S. Department of Energy EMCBC EM-Oak Ridge 23NE000003See Block 16CP00026  11 13. THIS ITEM ONLY APPLIES TO MODIFICATION OF CONTRACTS/ORDERS.  IT MODIFIES THE CONTRACT/ORDER NO. AS DESCRIBED IN ITEM 14. 12. ACCOUNTING AND APPROPRIATION DATA (If required) is not extended.is extended,  Items 8 and 15, and returning Offers must acknowledge receipt of this amendment prior to the hour and date specified in the solicitation or as amended , by one of the following methods: (a) By completing The above numbered solicitation is amended as set forth in Item 14.  The hour and date specified for receipt of Offers 11. THIS ITEM ONLY APPLIES TO AMENDMENTS OF SOLICITATIONS FACILITY CODE CODE  10B. DATED (SEE ITEM 13) 10A. MODIFICATION OF CONTRACT/ORDER NO. 9B. DATED (SEE ITEM 11) 9A. AMENDMENT OF SOLICITATION NO. CODE  8. NAME AND ADDRESS OF CONTRACTOR (No., street, county, State and ZIP Code) 7. ADMINISTERED BY (If other than Item 6)CODE 6. ISSUED BY PAGE   OF  PAGES 4. REQUISITION/PURCHASE REQ. NO.3. EFFECTIVE DATE2. AMENDMENT/MODIFICATION  NO. 5. PROJECT NO. (If applicable) 1.  CONTRACT ID CODE AMENDMENT OF SOLICITATION/MODIFICATION OF CONTRACT 05/31/2019 Attn: Charles Kerner 6901 Rockledge Dr Ste 800 Bethesda MD 208171867 Net Increase: $2,640,000.00 CHECK ONE A. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority)  THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT B. THE ABOVE NUMBERED CONTRACT/ORDER IS MODIFIED TO REFLECT THE ADMINISTRATIVE CHANGES (such as changes in paying office,  C. THIS SUPPLEMENTAL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: D. OTHER (Specify type of modification and authority)  appropriation data, etc.)  SET FORTH IN ITEM 14, PURSUANT TO THE AUTHORITY OF FAR 43.103(b). E. IMPORTANT: Contractor is not is required to sign this document and return    __________________ copies to the issuing office.  ORDER NO. IN ITEM 10A. 52.232-22  --  Limitation  of  Funds x 14. DESCRIPTION OF AMENDMENT/MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) X UEI:  L8VHV5CNBV97 The purpose of this incremental funding modifation is to obligate funds of +$2,640,000.00 from $156,300,188.63 by +$2,640,000.00 to $158,940,188.63.   The total contract value is hereby increased from $156,300,188.63 by $2,640,000.00 to $158,940,188.63. The All other terms and conditions remain unchanged and are in full force and effect. Period of Performance: 05/31/2019 to 11/30/2022 16A. NAME  AND TITLE OF CONTRACTING OFFICER (Type or print)15A. NAME AND TITLE OF SIGNER (Type or print) 15C. DATE SIGNED 16B. UNITED STATES OF AMERICA 15B. CONTRACTOR/OFFEROR 16C. DATE SIGNED (Signature of person authorized to sign) (Signature of Contracting Officer) Jeffrey C. Fogg STANDARD FORM 30 (REV. 11/2016) Prescribed by GSA FAR (48 CFR) 53.243 Previous edition unusable Except as provided herein, all terms and conditions of the document referenced in Item 9 A or 10A, as heretofore changed, remains unchanged and in full force and effect . 10/19/2022Exhibit
10.1

 

FINANCING
TERM SHEET

BY

PROVECTUS
BIOPHARMACEUTICALS, INC.

DATED
EFFECTIVE: September 20, 2022

 

The
following is a summary of the terms and conditions of a proposed financing plan (the “Plan”) developed by Provectus
Biopharmaceuticals, Inc. (the “Company”). The Plan was approved by the Board of Directors of the Company (the “Board”)
on September 20, 2022.

 

	Total
    Financing Commitment	This
    Financing Term Sheet (the “2022 Term Sheet”) envisions that the Company shall use its best efforts to arrange
    for a financing of a maximum of $5 million (the “2022 Financing”), which amounts may be provided in several tranches.
	 	 
	Structure
    of the Financing	The
    structure of the 2022 Financing shall be in the form of an unsecured convertible loan (the “Loan”) from various
    investors (collectively, the “Investors”). The Loan shall be evidenced by one or more convertible promissory notes
    (the “2022 Notes”) from the Company to each Investor.

 

The
2021 Notes may voluntarily or automatically convert into shares of Series D-1 Convertible Preferred Stock of the Company on or before
twelve (12) months after the issue date of a 2022 Note, subject to certain exceptions.

 

In
addition to customary provisions, the 2022 Notes shall contain the following provisions:

 

	 	(i)	that
    the Loan will bear unsecured;
	 	 	 
	 	(ii)	that
    the Loan will bear interest at the rate of eight percent (8%) per annum on the outstanding principal amount of the Loan that has
    been funded to the Company;
	 	 	 
	 	(iii)	that
    in the event there is a change of control of the Company’s Board, the term of the 2022 Note shall be accelerated and all amounts
    due under the 2022 Note shall be immediately due and payable at the Investor’s option; and
	 	 	 
	 	(iv)	that
    the principal amount of the Loan and interest payable under the Loan, at the Investor’s option, shall be paid pack, converted
    into shares of the Company’s Series D-1 Convertible Preferred Stock, a series of preferred stock designated by the Board, at
    a price per share equal to $2.8620 (where the preferred stock shall be convertible into ten [10] shares of the Company’s Common
    Stock), or, in the event there is a future financing of the Company, converted into the equity securities and/or debt instruments
    of such financing.

 

	Use
    of Proceeds	The
    proceeds from the 2022 Financing shall be used to fund the Company’s drug discovery and development program, as currently constituted,
    and envisioned, and to fund the Company’s general and administrative expenses.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]